Recent Articles from Benzinga
Benzinga, founded in 2010 by Jason Raznick and headquartered in Detroit, Michigan, is a dynamic financial media and technology company dedicated to empowering individual investors with timely, actionable insights. Initially launched from Raznick’s basement with a modest $10,000 investment, the company has grown into a trusted resource, attracting approximately 25 million monthly readers through its innovative blend of real-time financial news, market analysis, and trading tools.
Website: https://www.benzinga.com
Gold ETFs are back in focus as bullion nears record highs, tech valuation concerns grow and rate-cut bets rise.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
The holiday season is here and retailers are expecting a trillion-dollar shopping season. Wall Street is watching value-driven and e-commerce retailers for investment opportunities.
Via Benzinga · December 15, 2025
Bitcoin (CRYPTO: BTC) and Ethereum
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Phillips 66 sets a $2.4 billion budget for 2026, with $1.3 billion allocated for growth initiatives, including NGL and refining projects.
Via Benzinga · December 15, 2025
Shares of JPMorgan Chase (NASDAQ: JPM) are trending higher on Monday. Here's what investors need to know.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Norwegian Cruise (NCLH) stock flashes a Death Cross just as Leadership change adds uncertainty in turbulent market.
Via Benzinga · December 15, 2025
Dogecoin (CRYPTO: DOGE) is down over 4% on Monday, with the chart signaling downside risk toward the $0.08 area rather than
Via Benzinga · December 15, 2025
Sanofi expands its partnership with Dren Bio in a deal featuring $100 million upfront and up to $1.7 billion tied to a next-generation autoimmune B-cell therapy.
Via Benzinga · December 15, 2025
BofA raised Johnson & Johnson's price target to $220, citing steady growth, but sees limited upside from its pipeline through 2026.
Via Benzinga · December 15, 2025
Micron Technology Inc (NASDAQ:MU) shares climbed on Monday after Wedbush reiterated its bullish stance and lifted its price target.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Keybanc lowers ServiceNow rating during slowing SaaS growth, rising AI pressures, and potential loss of AI orchestration leadership to Microsoft in 2026.
Via Benzinga · December 15, 2025
Lennar reports Q4 financial results Tuesday. The earnings could be closely watched by investors to see how the housing market is doing.
Via Benzinga · December 15, 2025
Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and improving risk-reward outlook.
Via Benzinga · December 15, 2025
Applied Digital Corp (NASDAQ:APLD) shares are trending on Monday amid a sharp decline. Here's a look at what you need to know.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Retail traders with a very high risk tolerance might look for a "zombie squeeze" from iRobot.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Wall Street traded little changed Monday after last Friday’s tech-led sell-off failed to trigger meaningful dip-buying interest. By midday trading in New York, major indexes hovered near flat levels as investors stayed cautious ahead of a dense macro calendar this week.
Via Benzinga · December 15, 2025
Pfizer to provide full-year 2026 financial guidance on Tuesday. BofA analyst expects flat growth, reiterates Neutral rating.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Via Benzinga · December 15, 2025
Immunome stock surges after positive results from Phase 3 trial for desmoid tumors, meeting all key endpoints.
Via Benzinga · December 15, 2025
Visa Inc.
Via Benzinga · December 15, 2025
Alphabet's SpaceX stake may boost its earnings again, putting Alphabet-heavy ETFs in focus as private-market gains ripple into public ETF returns.
Via Benzinga · December 15, 2025
The Patrick Mahomes injury and Kansas City Chiefs missing the NFL Playoffs in the 2025 season could be bad news for Amazon stock. Here's why.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Luminar shares are under heavy pressure Monday after the company announced that it initiated voluntary Chapter 11 proceedings.
Via Benzinga · December 15, 2025
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.
Via Benzinga · December 15, 2025
Small Caps Outperforming Please click here for an enlarged chart of small cap iShares Russell 2000 ETF
Via Benzinga · December 15, 2025
Apple's iPhone 17 delivery lead times are rising across the US, China, and Europe, signaling resilient demand and supporting expectations for strong iPhone revenue growth into early 2026.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Radiopharm Theranostics shares rise after interim Phase 2b data showed 92% MRI concordance for RAD 101 imaging in brain metastases.
Via Benzinga · December 15, 2025
CrowdStrike introduces Falcon AI Detection and Response, expanding its platform to secure the AI prompt and agent interaction layer.
Via Benzinga · December 15, 2025
Artificial intelligence dominates market conversations, spawning two competing investment narratives. One rides on blockchain promises and decentralized computing dreams. The other ships actual chips, generates billions in profit, and pays real dividends. As we head toward 2026, the gap between AI cryptocurrency tokens and traditional AI stocks isn’t just wide.
Via Benzinga · December 15, 2025
Palvella Therapeutics reports Phase 2 data showing 73% improvement with QTORIN rapamycin gel in cutaneous venous malformations.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
A growth-first mindset is pushing markets higher. This breakdown explains the "Run It Hot" trade and where investors may be mispricing risk.
Via Benzinga · December 15, 2025
AMCX shares rally as Netflix, Paramount, and Warner Bros Discovery compete for acquisition. Seaport Research downgrades rating due to declining trends.
Via Benzinga · December 15, 2025
Canopy Growth Corp. (NASDAQ: CGC) to acquire MTL Cannabis Corp. (OTCQX: MTLNF) for approx. 125 million CAD in cash and stock.
Via Benzinga · December 15, 2025
Carnival Corp (CCL) to report Q2 results on 12/18. Analyst maintains Buy rating, expects in-line results. Stock may benefit from new destination and diversification.
Via Benzinga · December 15, 2025
Analyst upgrades Trane Technologies to Overweight and praises its strong CHVAC portfolio and potential in the data center market. Price target: $500.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Shares of BitMine Immersion Technologies, Inc. (NASDAQ:BMNR) are trading lower Monday.
Via Benzinga · December 15, 2025
Via Benzinga · December 15, 2025
Greenwich LifeSciences stock rose after Phase 3 data showed GLSI-100 cut breast cancer recurrence rates by about 80% in new patients.
Via Benzinga · December 15, 2025
Hashdex Asset Management recommends investors allocate 5%-10% to crypto as it becomes an essential part of portfolios due to macro pressures and growing institutional acceptance. Tokenization, AI, and stablecoins contribute to the growth of digital assets in the next 5 years.
Via Benzinga · December 15, 2025